TrialJournal of acquired immune deficiency syndromes (1999)2010

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

Jeffrey L Lennox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.